{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:49:17Z","timestamp":1789411757310,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.tube.2022.102271","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T03:48:58Z","timestamp":1666237738000},"page":"102271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Pharmacogenetic variability and the probability of site of action target attainment during tuberculosis meningitis treatment: A physiologically based pharmacokinetic modeling and simulations study"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-6436","authenticated-orcid":false,"given":"Krina","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navaneeth","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Heysell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Bisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvakumar","family":"Subbian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kurepina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry N.","family":"Kreiswirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Vinnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2022.102271_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/wellcomeopenres.15573.1","article-title":"Knowledge gaps and research priorities in tuberculous meningitis","volume":"4","author":"Seddon","year":"2019","journal-title":"Wellcome Open Res"},{"issue":"11","key":"10.1016\/j.tube.2022.102271_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-017-0796-0","article-title":"Tuberculous meningitis in children and adults: new insights for an ancient foe","volume":"17","author":"Mezochow","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"7","key":"10.1016\/j.tube.2022.102271_bib3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciw566","article-title":"Executive summary: official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.tube.2022.102271_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","author":"Heemskerk","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.tube.2022.102271_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01014-18","article-title":"Double-blind, randomized, placebo-controlled phase II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis","volume":"62","author":"Dian","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2022.102271_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17512433.2019.1552831","article-title":"Intensified antibiotic treatment of tuberculosis meningitis","volume":"12","author":"Cresswell","year":"2019","journal-title":"Expet Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.tube.2022.102271_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJMe1511990","article-title":"Chemotherapy for tuberculous meningitis","volume":"374","author":"Donald","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.tube.2022.102271_bib8","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMe1811861","article-title":"The coming of age of drug-susceptibility testing for tuberculosis","volume":"379","author":"Cox","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.tube.2022.102271_bib9","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiu610","article-title":"Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia","volume":"211","author":"Gumbo","year":"2015","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.tube.2022.102271_bib10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2217\/pgs-2018-0166","article-title":"Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis","volume":"20","author":"Naidoo","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.tube.2022.102271_bib11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/bcp.13172","article-title":"Isoniazid clearance is impaired among human immunodeficiency virus\/tuberculosis patients with high levels of immune activation","volume":"83","author":"Vinnard","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.tube.2022.102271_bib12","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/jac\/dkx111","article-title":"Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB","volume":"72","author":"Vinnard","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.tube.2022.102271_bib13","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/AAC.00353-10","article-title":"Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations","volume":"54","author":"Weiner","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.tube.2022.102271_bib14","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.tube.2022.102271_bib15","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1093\/cid\/civ426","article-title":"Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.tube.2022.102271_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/cid\/ciw763","article-title":"Long-term mortality of patients with tuberculous meningitis in New York city: a cohort study","volume":"64","author":"Vinnard","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2022.102271_bib17","doi-asserted-by":"crossref","first-page":"c4451","DOI":"10.1136\/bmj.c4451","article-title":"Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study","volume":"341","author":"Vinnard","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.tube.2022.102271_bib18","author":"Woods","year":"2011"},{"issue":"10","key":"10.1016\/j.tube.2022.102271_bib19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/psp4.12343","article-title":"PBPK models for CYP3A4 and P-gp ddi prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin","volume":"7","author":"Hanke","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.tube.2022.102271_bib20","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.tube.2022.102271_bib21","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1128\/AAC.00508-16","article-title":"A physiologically based pharmacokinetic model of isoniazid and its application in individualizing tuberculosis chemotherapy","volume":"60","author":"Cordes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.tube.2022.102271_bib22","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/psp4.12473","article-title":"Open systems Pharmacology community\u2014an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences","volume":"8","author":"Lippert","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"10.1016\/j.tube.2022.102271_bib23","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/cid\/ciab162","article-title":"High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly human immunodeficiency virus (HIV)-Positive Ugandan adults: a phase II open-label randomized controlled trial","volume":"73","author":"Cresswell","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.tube.2022.102271_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/clpt.1991.2","article-title":"Effect of steroids on CSF penetration of antituberculous drugs in tuberculous meningitis","volume":"49","author":"Kaojarern","year":"1991","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.tube.2022.102271_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12864-016-3298-6","article-title":"Genomic epidemiology of Lineage 4 Mycobacterium tuberculosis subpopulations in New York city and New Jersey, 1999-2009","volume":"17","author":"Brown","year":"2016","journal-title":"BMC Genom"},{"key":"10.1016\/j.tube.2022.102271_bib26","series-title":"Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes","author":"Woods","year":"2011"},{"issue":"5","key":"10.1016\/j.tube.2022.102271_bib27","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/cts.12769","article-title":"Genetic diversity in drug transporters: impact in african populations","volume":"13","author":"Rajman","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.tube.2022.102271_bib28","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.00185-07","article-title":"Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.tube.2022.102271_bib29","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.tube.2022.102271_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-018-0490-9","article-title":"Treatment of tuberculous meningitis and its complications in adults","volume":"20","author":"Davis","year":"2018","journal-title":"Curr Treat Options Neurol"},{"issue":"10","key":"10.1016\/j.tube.2022.102271_bib31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14787210.2013.839381","article-title":"Bacterial meningitis: new therapeutic approaches","volume":"11","author":"Nau","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.tube.2022.102271_bib32","first-page":"70","article-title":"Pharmacokinetics and safety\/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis","author":"Ruslami","year":"2021","journal-title":"Arch Dis Child"},{"issue":"8","key":"10.1016\/j.tube.2022.102271_bib33","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/cid\/ciz1071","article-title":"Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials","volume":"71","author":"Svensson","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.tube.2022.102271_bib34","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cpt.1783","article-title":"Pharmacokinetics and pharmacodynamics of intensive antituberculosis treatment of tuberculous meningitis","volume":"107","author":"Ding","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.tube.2022.102271_bib35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and safety of high-dose rifampin in pulmonary tuberculosis a randomized controlled trial","volume":"198","author":"Vel\u00e1squez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.tube.2022.102271_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/Spectrum.00610-21","article-title":"A rapid drug resistance genotyping workflow for Mycobacterium tuberculosis, using targeted isothermal amplification and nanopore sequencing","volume":"9","author":"Gliddon","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.tube.2022.102271_bib37","doi-asserted-by":"crossref","first-page":"102085","DOI":"10.1016\/j.tube.2021.102085","article-title":"Improving host-directed therapy for tuberculous meningitis by linking clinical and multi-omics data","volume":"128","author":"van Crevel","year":"2021","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2022.102271_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/wellcomeopenres.14006.2","article-title":"Adjunctive dexamethasone for the treatment of hiv-uninfected adults with tuberculous meningitis stratified by leukotriene a4 hydrolase genotype (LAST ACT): study protocol for a randomised double blind placebo controlled non-inferiority trial [version 1; r","volume":"3","author":"Donovan","year":"2018","journal-title":"Wellcome Open Res"},{"issue":"3","key":"10.1016\/j.tube.2022.102271_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jinf.2004.02.010","article-title":"Tuberculous meningitis and miliary tuberculosis: the Rich focus revisited","volume":"50","author":"Donald","year":"2005","journal-title":"J Infect"},{"issue":"2","key":"10.1016\/j.tube.2022.102271_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/CMR.00042-07","article-title":"Central nervous system tuberculosis: pathogenesis and clinical aspects","volume":"21","author":"Rock","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.tube.2022.102271_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-1625-9","article-title":"Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis","volume":"16","author":"Singh","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.tube.2022.102271_bib42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jps.24214","article-title":"A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation","volume":"104","author":"Thiel","year":"2015","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.tube.2022.102271_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics9060307","article-title":"Influence of single nucleotide polymorphisms on rifampin pharmacokinetics in tuberculosis patients","volume":"9","author":"Thomas","year":"2020","journal-title":"Antibiotics"},{"issue":"7","key":"10.1016\/j.tube.2022.102271_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00210-17","article-title":"Genetic determinants of the pharmacokinetic variability of rifampin in Malawian adults with pulmonary tuberculosis","volume":"61","author":"Sloan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5930","key":"10.1016\/j.tube.2022.102271_bib45","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1126\/science.1172257","article-title":"The genetic structure and history of Africans and African Americans","volume":"324","author":"Tishkoff","year":"2009","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.tube.2022.102271_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02174-18","article-title":"Low antituberculosis drug concentrations in HIV-tuberculosis-coinfected adults with low body weight: is it time to update dosing guidelines?","volume":"63","author":"Sekaggya-Wiltshire","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.tube.2022.102271_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00140-21","article-title":"Plasma pharmacokinetics of high-dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial","volume":"65","author":"Wasserman","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979222001081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979222001081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:46:38Z","timestamp":1761468398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979222001081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":47,"alternative-id":["S1472979222001081"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2022.102271","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetic variability and the probability of site of action target attainment during tuberculosis meningitis treatment: A physiologically based pharmacokinetic modeling and simulations study","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2022.102271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102271"}}